Press coverage about Irhythm Technologies (NASDAQ:IRTC) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Irhythm Technologies earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the company an impact score of 43.909633220631 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Several analysts have recently issued reports on IRTC shares. BidaskClub cut shares of Irhythm Technologies from a “hold” rating to a “sell” rating in a research note on Thursday, December 14th. Zacks Investment Research cut shares of Irhythm Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Dougherty & Co assumed coverage on shares of Irhythm Technologies in a research report on Friday, December 1st. They set a “neutral” rating for the company. Canaccord Genuity boosted their price objective on shares of Irhythm Technologies from $55.00 to $59.00 and gave the stock a “buy” rating in a report on Thursday, November 2nd. Finally, ValuEngine upgraded shares of Irhythm Technologies from a “sell” rating to a “hold” rating in a report on Saturday, October 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $65.25.
Irhythm Technologies (NASDAQ IRTC) traded up $1.98 on Friday, reaching $62.62. 212,223 shares of the company traded hands, compared to its average volume of 158,711. The firm has a market capitalization of $1,393.60, a price-to-earnings ratio of -52.62 and a beta of 2.79. Irhythm Technologies has a 52-week low of $28.70 and a 52-week high of $62.95. The company has a current ratio of 7.65, a quick ratio of 7.57 and a debt-to-equity ratio of 0.38.
Irhythm Technologies (NASDAQ:IRTC) last posted its earnings results on Wednesday, November 1st. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.05. The firm had revenue of $25.04 million during the quarter, compared to analysts’ expectations of $24.30 million. Irhythm Technologies had a negative net margin of 27.56% and a negative return on equity of 27.67%. Irhythm Technologies’s quarterly revenue was up 49.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.80) EPS. equities analysts anticipate that Irhythm Technologies will post -1.17 EPS for the current year.
In related news, insider Kevin M. King sold 60,000 shares of the stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $51.85, for a total transaction of $3,111,000.00. Following the completion of the sale, the insider now directly owns 103,042 shares of the company’s stock, valued at $5,342,727.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Matthew C. Garrett sold 1,193 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $55.00, for a total transaction of $65,615.00. The disclosure for this sale can be found here. Insiders sold 536,533 shares of company stock valued at $28,333,506 over the last quarter. Insiders own 23.30% of the company’s stock.
Irhythm Technologies Company Profile
iRhythm Technologies, Inc is a United States-based digital health company. The Company develops and commercializes solutions that integrate biosensor technology, patient data, analytics and medical expertise. The Company offers flagship solution, the ZIO Service. Its ZIO Service consists of the ZIO XT Patch, algorithms and the ZIO Report.
Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.